Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valuing Genzyme: Adding A Health Care Reform Premium

Executive Summary

As Sanofi-Aventis's board mulls whether to up its offer for Genzyme, Wall Street is busy crunching the numbers, and there are plenty of factors to consider. Sanofi’s now-public offer is $69 per share in cash, or a total of $18.5 billion for the company. That represents about a 40% premium to Genzyme Corp.’s share price as of mid-July, when Sanofi’s interest became apparent.

You may also be interested in...



Orphan Drug “Improvements” May Be Undercut By New Market Share Fees

The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.

Orphan Drug “Improvements” May Be Undercut By New Market Share Fees

The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.

Taking Lumps From Health Care Reform

Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.

Related Content

Topics

UsernamePublicRestriction

Register

PS052688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel